What systemic condition is most associated with retinal vein occlusion?

Hypertension is the most commonly associated systemic condition, so blood pressure evaluation and cardiovascular risk assessment are an important part of the workup, alongside diabetes and hyperlipidemia screening.

How is vision loss from RVO treated?

Vision loss is most often due to macular edema, which is treated first-line with intravitreal anti-VEGF injections; corticosteroid implants are an alternative in selected patients.

What is the danger of ischemic central retinal vein occlusion?

Ischemic CRVO can lead to neovascularization of the iris and angle and neovascular glaucoma, so these eyes require close monitoring and prompt panretinal photocoagulation when new vessels appear.

RetinaOphthalmologyOptometry

Retinal Vein Occlusion

Also known as: RVO, BRVO, CRVO

Overview

Retinal vein occlusion (RVO) is one of the most common retinal vascular disorders, caused by thrombotic obstruction of a retinal vein that leads to hemorrhage, macular edema, and, in ischemic cases, neovascularization. It is classified as branch or central depending on the site of occlusion. Vision loss most often results from macular edema, which is treated effectively with anti-VEGF therapy.

LinkedIn Facebook X

Mechanism: Venous thrombosis in the retina
Types: Branch (BRVO), Central (CRVO)
Main cause of vision loss: Macular edema
First-line therapy: Intravitreal anti-VEGF

Key clinical points

Hypertension is the most common associated systemic condition, especially in branch RVO.
Ischemic central RVO carries a risk of neovascular glaucoma and requires close monitoring.
OCT guides diagnosis and treatment of macular edema.
Anti-VEGF therapy is first-line; corticosteroid implants are alternatives.
Panretinal photocoagulation treats neovascular complications.

Classification and risk factors

RVO is divided into branch occlusion, affecting a tributary vein at an arteriovenous crossing, and central occlusion at the level of the optic nerve. Each can be non-ischemic or ischemic; ischemia raises the risk of neovascularization. Associated systemic factors include hypertension, hyperlipidemia, diabetes, and, in younger patients, hypercoagulable states.

Diagnosis and workup

Fundus examination shows retinal hemorrhages in the distribution of the occluded vein, dilated tortuous vessels, and often macular edema. OCT quantifies edema, and fluorescein angiography characterizes perfusion and ischemia. A targeted systemic evaluation addresses modifiable cardiovascular risk factors, coordinated with the patient’s primary care team.

Treatment

Intravitreal anti-VEGF therapy is first-line for macular edema from both branch and central RVO and can improve vision substantially. Corticosteroid implants are useful alternatives, particularly in selected patients. Panretinal photocoagulation is applied when neovascularization develops, and ischemic central RVO warrants vigilant monitoring for anterior segment neovascularization and neovascular glaucoma.

Frequently asked questions

What systemic condition is most associated with retinal vein occlusion?: Hypertension is the most commonly associated systemic condition, so blood pressure evaluation and cardiovascular risk assessment are an important part of the workup, alongside diabetes and hyperlipidemia screening.
How is vision loss from RVO treated?: Vision loss is most often due to macular edema, which is treated first-line with intravitreal anti-VEGF injections; corticosteroid implants are an alternative in selected patients.
What is the danger of ischemic central retinal vein occlusion?: Ischemic CRVO can lead to neovascularization of the iris and angle and neovascular glaucoma, so these eyes require close monitoring and prompt panretinal photocoagulation when new vessels appear.

References & further reading

Retina

Diabetic Retinopathy

Diabetic retinopathy is a microvascular complication of diabetes mellitus and a leading cause of vision loss among working-age adults. It progresses from non-proliferative changes—microaneurysms, hemorrhages, and exudates—to proliferative disease with neovascularization that risks vitreous hemorrhage and tractional detachment. Glycemic and blood pressure control plus timely screening are the foundation of prevention.

Clinical overview Retina

Diabetic Macular Edema

Diabetic macular edema (DME) is the accumulation of fluid in the central retina due to breakdown of the blood–retinal barrier in diabetes, and it is the most common cause of vision loss in patients with diabetic retinopathy. It can occur at any stage of retinopathy. OCT has made diagnosis and monitoring precise, and anti-VEGF therapy is the first-line treatment for center-involving disease.